Aliases & Classifications for Spasticity

About this section

Aliases & Descriptions for Spasticity:

Name: Spasticity 49 27

Summaries for Spasticity

About this section
NINDS:49 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might

MalaCards based summary: Spasticity is related to spastic paraplegia 11 and spastic paraplegia 13. An important gene associated with Spasticity is DARS (Aspartyl-TRNA Synthetase). Affiliated tissues include spinal cord, t cells and brain.

Wikipedia:71 Spasticity (from Greek spasmos-, meaning \"drawing, pulling\") is a feature of altered skeletal muscle... more...

Related Diseases for Spasticity

About this section

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 644)
idRelated DiseaseScoreTop Affiliating Genes
1spastic paraplegia 1133.5KIF1A, SPG7
2spastic paraplegia 1331.9DDHD1, KIF1A, SPAST, TECPR2
3spinocerebellar degeneration23.7ATP6AP2, DARS, DDHD1, FAR1, KIF1A, MECP2
4hereditary spastic paraplegia12.3
5tropical spastic paraparesis12.2
6spastic hemiplegia12.2
7spastic diplegia12.1
8spastic quadriplegia12.1
9spastic paraplegia 712.1
10infantile-onset ascending hereditary spastic paralysis12.1
11spastic paraplegia 72, autosomal recessive12.1
12spastic paraplegia 2, x-linked12.1
13spastic paraplegia 3a, autosomal dominant12.1
14spastic paraplegia 412.1
15silver spastic paraplegia syndrome12.1
16spastic paraplegia 35, autosomal recessive12.0
17spastic paraplegia, optic atrophy, and neuropathy12.0
18ataxia, spastic, 412.0
19spastic paraplegia 11, autosomal recessive12.0
20spastic paraplegia 54, autosomal recessive12.0
21spastic paraplegia 812.0
22spastic cerebral palsy12.0
23spastic paraplegia 9a, autosomal dominant12.0
24spastic paraplegia 49, autosomal recessive12.0
25spastic paraplegia 15, autosomal recessive12.0
26ataxia, spastic, 5, autosomal recessive12.0
27spastic paraplegia 212.0
28spastic paraplegia 3a12.0
29spastic ataxia 1, autosomal dominant12.0
30spastic paraplegia 43, autosomal recessive12.0
31spastic paraplegia 4, autosomal dominant12.0
32spastic paraplegia 39, autosomal recessive12.0
33spastic paraplegia 5a, autosomal recessive12.0
34spastic paraplegia 30, autosomal recessive12.0
35spastic paraplegia 56, autosomal recessive12.0
36spastic paraplegia 53, autosomal recessive12.0
37spastic paraplegia 8, autosomal dominant12.0
38spastic paraplegia 10, autosomal dominant12.0
39troyer syndrome12.0
40spastic paraplegia 26, autosomal recessive12.0
41spastic paraplegia 12, autosomal dominant12.0
42spastic paraplegia 28, autosomal recessive12.0
43spastic paraplegia 7, autosomal recessive12.0
44spastic ataxia 2, autosomal recessive12.0
45spastic paraplegia 57, autosomal recessive12.0
46spastic paraplegia 18, autosomal recessive12.0
47spastic paraplegia 46, autosomal recessive12.0
48spastic paraplegia 55, autosomal recessive12.0
49spastic paraplegia 6312.0
50spastic paraplegia 45, autosomal recessive12.0

Graphical network of the top 20 diseases related to Spasticity:



Diseases related to spasticity

Symptoms & Phenotypes for Spasticity

About this section

Drugs & Therapeutics for Spasticity

About this section

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 287)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BaclofenapprovedPhase 4, Phase 3, Phase 1, Phase 2951134-47-02284
Synonyms:
( inverted question mark)-Baclofen
(+-)-Baclofen
(+/-)- beta-(Aminoethyl)-4- chlorobenzenepropanoic acid
(+/-)-BACLOFEN
(+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
(?)-Baclofen
1134-47-0
4-Amino-3-(4-chlorophenyl)butanoic acid
4-Amino-3-(4-chlorophenyl)butyric acid
62594-36-9
AB00051921
AC-4530
AC1L1DC6
ASTA Medica Brand of Baclofen
AWD, Baclofen
Alphapharm Brand of Baclofen
Apo Baclofen
Apo-Baclofen
ApoBaclofen
Apotex Brand of Baclofen
Ashbourne Brand of Baclofen
Athena Brand of Baclofen
Atrofen
B 5399
B3343
B5399_SIGMA
BPBio1_000012
BPBio1_000750
BRD-A84174873-001-05-2
BRN 2104494
BSPBio_000010
BSPBio_001880
Ba 34647
Ba-34,647
Ba-34647
Ba34,647
Ba34647
Baclofen (JP15/USP/INN)
Baclofen (R,S)
Baclofen AWD
Baclofen Alphapharm Brand
Baclofen Apotex Brand
Baclofen Ashbourne Brand
Baclofen Athena Brand
Baclofen Ciba-Geigy Brand
Baclofen Irex Brand
Baclofen Isis Brand
Baclofen Medtronic Brand
Baclofen Novartis Brand
Baclofen Nu-Pharm Brand
Baclofen Pharmascience Brand
Baclofen [USAN:INN:BAN:JAN]
Baclofene
Baclofene Irex
Baclofene [INN-French]
Baclofene-Irex
BaclofeneIrex
Baclofeno
Baclofeno [INN-Spanish]
Baclofenum
Baclofenum [INN-Latin]
Baclon
Baclophen
Baclospas
Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI)
Biomol-NT_000251
C 34647Ba
C10H12ClNO2
CCRIS 3722
CHEBI:2972
CHEMBL701
CIBA-34,647-BA
CIBA34,647BA
CID2284
Chlorophenyl GABA
Ciba 34,647-Ba
Ciba Geigy Brand of Baclofen
Ciba-Geigy Brand of Baclofen
Clofen
D001418
D00241
DB00181
DL-4-Amino-3-P-chlorophenylbutanoic acid
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
 
DivK1c_000001
EINECS 214-486-9
EU-0100163
GABA, Chlorophenyl
Gabalon
Gen Baclofen
Gen-Baclofen
GenBaclofen
Genpharm
HMS1568A12
HMS1920E21
HMS2091M03
HMS500A03
I01-1934
IDI1_000001
Irex Brand of Baclofen
Isis Brand of Baclofen
KBio1_000001
KBio2_000466
KBio2_003034
KBio2_005602
KBio3_001380
KBioGR_000650
KBioSS_000466
Kemstro
Kemstro (TN)
L000002
LS-77134
Lebic
Lioresal
Lioresal (TN)
Lioresal Intrathecal
Lopac0_000163
MLS000028480
Medtronic Brand of Baclofen
MolPort-002-051-370
NCGC00015156-05
NCGC00015156-12
NCGC00023843-03
NCGC00024579-03
NCGC00024579-04
NCGC00024579-05
NCGC00024579-06
NINDS_000001
NSC329137
Novartis Brand of Baclofen
Nu Baclo
Nu Pharm Brand of Baclofen
Nu-Baclo
Nu-Baclofen
Nu-Pharm Brand of Baclofen
NuBaclo
Oprea1_440627
PCP-GABA
PMS Baclofen
PMSBaclofen
Pharmascience Brand of Baclofen
Pms-Baclofen
Prestwick0_000085
Prestwick1_000085
Prestwick2_000085
Prestwick3_000085
Prestwick_85
SMP1_000036
SMR000058294
SPBio_000044
SPBio_001949
SPECTRUM1500135
STK535284
STOCK2S-30552
Spectrum2_000092
Spectrum3_000310
Spectrum4_000245
Spectrum5_000852
Spectrum_000066
UNII-H789N3FKE8
UPCMLD-DP142
UPCMLD-DP142:001
baclofen
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-P-chlorohydrocinnamic acid
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
beta-(P-Chlorophenyl)-gamma-aminobutyric acid
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
gamma-Amino-beta-(P-chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyric acid
2
EthanolapprovedPhase 4, Phase 3, Phase 2204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
3
DopamineapprovedPhase 4375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4
LevodopaapprovedPhase 438859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
5
Memantineapproved, investigationalPhase 417619982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
6
Dronabinolapproved, illicitPhase 4, Phase 3, Phase 2, Phase 11381972-08-316078, 2978
Synonyms:
(-)- delta 9-Tetrahydrocannabinol
(-)-.DELTA.1-Tetrahydrocannabinol
(-)-.DELTA.9-THC
(-)-.DELTA.9-Tetrahydrocannabinol
(-)-.DELTA.9-trans-Tetrahydrocannabinol
(-)-.delta.(sup9)-trans-Tetrahydrocannabinol
(-)-3,4-trans-Delta1-Tetrahydrocannabinol
(-)-delta (sup9)-trans-Tetrahydrocannabinol
(-)-delta 1-Tetrahydrocannabinol
(-)-delta 9-THC
(-)-delta 9-trans-Tetrahydrocannabinol
(-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol
(-)-delta1-Tetrahydrocannabinol
(-)-delta9-(trans)-Tetrahydrocannabinol
(-)-delta9-Tetrahydrocannabinol
(-)-delta9-trans-Tetrahydrocannabinol
(-)-trans-.DELTA.9-Tetrahydrocannabinol
(-)-trans-Delta1-Tetrahydrocannabinol
(-)-trans-Delta9-THC
(-)-trans-delta 1-Tetrahydrocannabinol
(-)-trans-delta 9-THC
(-)-trans-delta 9-Tetrahydrocannabinol
(-)-trans-delta9-Tetrahydrocannabinol
(L)-.delta.1-Tetrahydrocannabinol
(L)-delta 1-Tetrahydrocannabinol
(l)-delta(sup 1)-Tetrahydrocannabinol
(l)-delta1-Tetrahydrocannabinol
.DELTA.1-THC
.DELTA.1-Tetrahydrocannabinol
.DELTA.9-THC
.DELTA.9-trans-Tetrahydrocannabinol
.delta.(sup9)-THC
.delta.-9-THC
1-trans-.delta.(sup9)-tetrahydrocannabinol
1-trans-D9-Tetrahydrocannabinol
1-trans-delta (sup9)-tetrahydrocannabinol
1-trans-delta 9-Tetrahydrocannabinol
1-trans-delta(sup 9)-Tetrahydrocannabinol
1-trans-delta(sup9)-tetrahydrocannabinol
1-trans-delta-9-Tetrahydrocannabinol
1-trans-delta9-Tetrahydrocannabinol
1363-19-5
14146-29-3
14146-43-1
14C-.DELTA.1-Tetrahydrocannabinol
14C-delta 1-Tetrahydrocannabinol
1972-08-3
26108-45-2
3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,D)pyran-1-ol
308064-99-5
5957-27-7
6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
6465-30-1
6H-Dibenzo
9-delta-Tetrahydrocannabinol
9-ene-Tetrahydrocannabinol
9-tetrahydrocannabinol
AC1L277U
AC1Q2VRZ
Abbott 40566
BIDD:GT0427
C06972
CAT-310
CCRIS 4726
CHEBI:104496
CHEMBL465
CID16078
Cannabinol, Delta1-tetrahydro- (7CI)
Cannabinol, tetrahydro- (6CI)
Cannabis resin
Compassia
D00306
DB00470
DEA No. 7369
DEA No. 7370
DRG-0138
Delta9-Tetrahydrocannabinol solution
Deltanyne
Drona binol
Dronabinol
Dronabinol (USP/INN)
Dronabinol [USAN:INN]
Dronabinolum
Dronabinolum [Latin]
 
EPA 28
EPA-PLUS
Exocyclic delta (9)(11)-Tetrahydrocannabiol
Fats and Glyceridic oils, fish, n-3 fatty acid-high
Fish oils, n-3 fatty acid-high
Fish oils, omega-3 fatty acid-high
Ganja
HSDB 6471
Hashish
L-.delta.1-Tetrahydrocannabinol
L-.delta.1-trans-Tetrahydrocannabinol
L-delta 1-trans-Tetrahydrocannabinol
L-delta(sup 1)-tetrahydrocannabinol
L-delta1-trans-Tetrahydrocannabinol
L-trans-.delta.9-Tetrahydrocannabinol
L-trans-delta 9-Tetrahydrocannabinol
L-trans-delta9-Tetrahydrocannabinol
LS-975
Marincap
Marinol
Marinol (TN)
MaxEPA
MolPort-003-959-698
NSC 134454
NSC134454
Namisol
Omegaven
PDSP2_000714
Primolut
Pro-Mega
Promega
QCD 84924
QCD-84924
Relivar
SP 104
Sonergx
T2386_SIGMA
T4764_FLUKA
T4764_SIGMA
TETRAHYDROCANNABINOL
THC
THC-delta-9
Tetrahydrocannabinol
Tetrahydrocannabinol delta9
Tetrahydrocannabinols (-)-delta1-3,4-trans-form
Tetranabinex
UNII-7J8897W37S
ZINC01530625
delta (sup9)-Thc
delta 1-THC
delta 1-Tetrahydrocannabinol
delta 9-THC
delta 9-Tetrahydrocannabinol
delta 9-trans-Tetrahydrocannabinol
delta(1)-THC
delta(1)-Tetrahydrocannabinol
delta(9)-THC
delta(9)-Tetrahydrocannabinol
delta(9)-Tetrahydrocannibinol
delta(sup 1)-Tetrahydrocannabinol
delta(sup 1)-Thc
delta(sup 9)-Tetrahydrocannabinol
delta(sup 9)-Thc
delta-9-THC
delta-9-Tetrahydrocannabinol
delta-9-tetrahydrocannabinol
delta-THC
delta1-THC
delta1-Tetrahydrocannabinol
delta1-Tetrahydrocannabinol (VAN)
delta9-THC
delta9-Tetrahydrocannabinol
delta9-Tetrahydrocannabinol (VAN)
delta9-trans-Tetrahydrocannabinol
nchembio.129-comp1
nchembio.552-comp1
nchembio.86-comp3
omega-3-Fatty acid
trans-.DELTA.9-Tetrahydrocannabinol
trans-delta (-)-9-Tetrahydrocannabinol
trans-delta 9-Tetrahydrocannabinol
trans-delta-9-Tetrahydrocannabinol
trans-delta9-Tetrahydrocannabinol
trans-tetrahydrocannabinol
Δ9-tetrahydrocannabinol
7
AcetylcholineapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 177651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
8
Lidocaineapproved, vet_approvedPhase 4, Phase 21226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
9
TizanidineapprovedPhase 4, Phase 3, Phase 1, Phase 22051322-75-95487
Synonyms:
5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole
5-chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiadiazole
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
51322-75-9
64461-82-1 (mono-hydrochloride)
AC1L1KGE
BIDD:GT0580
BRN 0618691
C07452
C9H8ClN5S
CHEBI:240117
CHEMBL1079
CID5487
D08611
DB00697
HMS2089B03
I01-2529
L001084
LS-40470
 
MolPort-002-508-203
NCGC00160529-01
NCGC00160529-02
NCGC00160529-03
NCGC00160529-04
NCGC00160529-05
STK711168
STOCK6S-26959
Sirdalud
Sirdalud (TN)
Ternelin
Tizanidin
Tizanidina
Tizanidina [INN-Spanish]
Tizanidine
Tizanidine (INN)
Tizanidine [INN:BAN]
Tizanidinum
Tizanidinum [INN-Latin]
UNII-6AI06C00GW
ZINC19702309
tizanidine
10
Bupivacaineapproved, investigationalPhase 411312180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
11PiracetamapprovedPhase 4, Phase 21707491-74-9
12
ClonidineapprovedPhase 4, Phase 3, Phase 1, Phase 22264205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
13
NorepinephrineapprovedPhase 468351-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
14
Gabapentinapproved, investigationalPhase 428960142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
15
IronapprovedPhase 411237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
16
DeferiproneapprovedPhase 45730652-11-02972
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
CP-20
DN-180-01-AF
Deferipron
 
Deferiprona
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
Défériprone
Ferriprox
PL-1
17Excitatory Amino AcidsPhase 4, Phase 21297
18Peppermint oilPhase 4, Phase 333
19Neuroprotective AgentsPhase 4, Phase 3, Phase 2, Phase 11672
20Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 112806
21Calcium, DietaryPhase 4, Phase 3, Phase 25525
22Antidepressive AgentsPhase 4, Phase 1, Phase 22666
23Antihypertensive AgentsPhase 4, Phase 3, Phase 1, Phase 24095
24GABA AgentsPhase 4, Phase 3, Phase 2, Phase 11622
25Excitatory Amino Acid AntagonistsPhase 4, Phase 21282
26
gamma-Aminobutyric AcidPhase 423056-12-2119
Synonyms:
3-Carboxypropylamine
4-Aminobutanoate
4-Aminobutanoic acid
4-Aminobutyrate
4-Aminobutyric acid
Aminalon
GABA
Gaballon
Gamarex
Gammalon
Gammalone
Gammar
Gammasol
 
Mielogen
Mielomade
Omega-Aminobutyrate
Omega-Aminobutyric acid
Piperidate
Piperidic acid
Piperidinate
Piperidinic acid
gamma Aminobutyrate
gamma Aminobutyric acid
gamma-Aminobutyrate
gamma-Aminobutyric acid
w-Aminobutyrate
w-Aminobutyric acid
27Tranquilizing AgentsPhase 4, Phase 3, Phase 2, Phase 14164
28AnticonvulsantsPhase 4, Phase 3, Phase 1, Phase 22620
29Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 117734
30onabotulinumtoxinAPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1626
31Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 122776
32Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
33Neuromuscular AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11129
34incobotulinumtoxinAPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1635
35Botulinum ToxinsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1669
36Botulinum Toxins, Type APhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1630
37Cholinergic AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13846
38Carbidopa, levodopa drug combinationPhase 4120
39DihydroxyphenylalaninePhase 4140
40AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111287
41calcium channel blockersPhase 4, Phase 31940
42Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 16279
43Neurotransmitter Uptake InhibitorsPhase 4, Phase 13464
44abobotulinumtoxinAPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1626
45Dopamine AgentsPhase 43759
46Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
47Adrenergic AgentsPhase 4, Phase 3, Phase 1, Phase 25140
48Antiparkinson AgentsPhase 4, Phase 11527
49Antimanic AgentsPhase 4, Phase 3, Phase 1, Phase 2790
50Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 121402

Interventional clinical trials:

(show top 50)    (show all 566)
idNameStatusNCT IDPhase
1Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal SpasticityUnknown statusNCT01786005Phase 4
2The Efficacy and Safety of MEDITOXIN® in Children With Cerebral PalsyUnknown statusNCT01256021Phase 4
3Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?Unknown statusNCT00752934Phase 4
4The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia PatientsUnknown statusNCT01664013Phase 4
5Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled StudyUnknown statusNCT01361373Phase 4
6Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord InjuryUnknown statusNCT00201968Phase 4
7Vanderbilt University Spasticity Management Program Evaluation PlanCompletedNCT00179114Phase 4
8SISTERS: Spasticity In Stroke Study - Randomized StudyCompletedNCT01032239Phase 4
9Asian Botulinum Clinical Trial Designed for Early Stroke SpasticityCompletedNCT00234546Phase 4
10BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb SpasticityCompletedNCT00430196Phase 4
11Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the ArmCompletedNCT00216411Phase 4
12BOTOX® Economic Spasticity Trial (BEST)CompletedNCT00549783Phase 4
13Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity ProgressionCompletedNCT02321436Phase 4
14Memantine for Spasticity in MS PatientsCompletedNCT00638027Phase 4
15Comparative Efficacy of Three Preparations of Botox-A in Treating SpasticityCompletedNCT00178646Phase 4
16A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis PatientsCompletedNCT01964547Phase 4
17Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral PalsyCompletedNCT01276015Phase 4
18Botulinum Toxin A Adult Gastrocnemius Muscle StudyCompletedNCT01278576Phase 4
19SynchroMed II Post-Approval StudyCompletedNCT00773019Phase 4
20Recurrent Crying Spells in Cerebral PalsyCompletedNCT01955655Phase 4
21Myobloc Atrophy StudyCompletedNCT02052024Phase 4
22Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic PatientsCompletedNCT01460277Phase 4
23Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord InjuryCompletedNCT00252954Phase 4
24Tizanidine and Superficial Cervical Block on Pain After ThyroidectomyCompletedNCT02725359Phase 4
25Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.CompletedNCT00320281Phase 4
26Effects of Botulinum Toxin Type A in Adults With Cerebral PalsyCompletedNCT00432055Phase 4
27Project to Improve Symptoms and Mood in People With Spinal Cord InjuryCompletedNCT00592384Phase 4
28Post Marketing Surveillance Study of DysportCompletedNCT00210431Phase 4
29Study of the Effects on Motor Recovery of Early Post-stroke Spasticity TreatmentRecruitingNCT02462317Phase 4
30Intrathecal Baclofen (ITB) Delivery Location and Its Effect on SpasticityRecruitingNCT02903823Phase 4
31The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke AdultsRecruitingNCT02505802Phase 4
32Upper Extremity Rehabilitation Using Robot and Botulinum ToxinRecruitingNCT02228863Phase 4
33Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox)RecruitingNCT02888548Phase 4
34Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?RecruitingNCT02546999Phase 4
35Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After StrokeRecruitingNCT02114736Phase 4
36Upper Limb Botulinum Toxin Injection Combined With Self RehabilitationRecruitingNCT02699762Phase 4
37Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury PatientsRecruitingNCT02031835Phase 4
38Treatment for Alcohol Dependence With GabapentinRecruitingNCT02771925Phase 4
39Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis PatientsActive, not recruitingNCT01968902Phase 4
40Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial SiderosisActive, not recruitingNCT01284127Phase 4
41Meditoxin® Treatment in Patients With Post Stroke Upper Limb SpasticityNot yet recruitingNCT02757404Phase 4
42The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following StrokeNot yet recruitingNCT02944929Phase 4
43Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke SpasticityNot yet recruitingNCT02358005Phase 4
44Effects of Functional Electrical Stimulation on Gait in Children With Cerebral PalsyNot yet recruitingNCT02462018Phase 4
45Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)Not yet recruitingNCT02969356Phase 4
46Bilateral Versus Unilateral Task Retraining Using the SaeboFlex OrthosisTerminatedNCT00893776Phase 4
47Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral PalsyTerminatedNCT00549471Phase 4
48Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided TechniquesTerminatedNCT00992108Phase 4
49Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After StrokeUnknown statusNCT01910363Phase 2, Phase 3
50Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron DiseaseUnknown statusNCT01776970Phase 2, Phase 3

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

About this section

Genetic tests related to Spasticity:

id Genetic test Affiliating Genes
1 Spasticity27

Anatomical Context for Spasticity

About this section

MalaCards organs/tissues related to Spasticity:

36
Spinal cord, T cells, Brain, Testes, Bone, Skeletal muscle, Cortex

Publications for Spasticity

About this section

Articles related to Spasticity:

(show top 50)    (show all 3173)
idTitleAuthorsYear
1
Clinical and genetic study of hereditary spastic paraplegia in Canada. (27957547)
2017
2
Co-existence of spastic paraplegia-30 with novel KIF1A mutation and spinocerebellar ataxia 31 with intronic expansion of BEAN and TK2 in a family. (28017198)
2017
3
Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. (27732905)
2017
4
Beneficial effects of rapamycin in a Drosophila model for hereditary spastic paraplegia. (27909242)
2017
5
ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. (27738760)
2017
6
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) with a novel DARS2 mutation and isolated progressive spastic paraparesis. (28017220)
2017
7
Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury. (28082177)
2017
8
Structured skill practice during intensive bimanual training leads to better trunk and arm control than unstructured practice in children with unilateral spastic cerebral palsy. (27912104)
2017
9
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. (28000352)
2017
10
The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis. (27845163)
2017
11
Spastic diplegia in preterm-born children: Executive function impairment and neuroanatomical correlates. (28073076)
2017
12
Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. (27894665)
2017
13
Plantar flexor muscle weakness and fatigue in spastic cerebral palsy patients. (28064025)
2017
14
Exome sequencing reveals two FA2H mutations in a family with a complicated form of Hereditary Spastic Paraplegia and psychiatric impairments. (28017243)
2017
15
Gross motor function in children with spastic Cerebral Palsy and Cerebral Visual Impairment: A comparison between outcomes of the original and the Cerebral Visual Impairment adapted Gross Motor Function Measure-88 (GMFM-88-CVI). (27771178)
2017
16
Genetic and phenotypic characterization of complex hereditary spastic paraplegia. (27217339)
2016
17
A novel SPAST frameshift mutation in a Chinese family with hereditary spastic paraplegia. (27629539)
2016
18
Predictors of Spasticity After Stroke. (27547509)
2016
19
Are electromyographic patterns during gait related to abnormality level of the gait in patients with spastic cerebral palsy? (27840431)
2016
20
Skeletal Maturation and Mineralisation of Children with Moderate to Severe Spastic Quadriplegia. (27504366)
2016
21
Establishment of SPAST mutant induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia (HSP) patient. (27789400)
2016
22
The effects of intensive bimanual training with and without tactile training on tactile function in children with unilateral spastic cerebral palsy: A pilot study. (26698408)
2016
23
Mechanical and material properties of the plantarflexor muscles and Achilles tendon in children with spastic cerebral palsy and typically developing children. (27515440)
2016
24
Intrathecal baclofen pumps do not accelerate progression of scoliosis in quadriplegic spastic cerebral palsy. (27154169)
2016
25
Defining the genetic basis of early onset hereditary spastic paraplegia using whole genome sequencing. (27679996)
2016
26
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study. (27570991)
2016
27
Effect of supporting 3D-garment on gait postural stability in children with bilateral spastic cerebral palsy. (27341370)
2016
28
Novel De Novo Mutations in KIF1A as a Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System Involvement. (27034427)
2016
29
Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous Y275X mutation in CYP7B1 (SPG5). (27879220)
2016
30
Correlation between transverse plan kinematics and foot progression angle in children with spastic diplegia. (27902635)
2016
31
Single-level selective dorsal rhizotomy for spastic cerebral palsy. (27757432)
2016
32
Spasticity secondary to Leigh syndrome managed with selective dorsal rhizotomy: a case report. (27041374)
2016
33
Multiparametric 3T MRI evaluation of hereditary spastic paraplegia: A case report. (27857457)
2016
34
Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. (27084214)
2016
35
Orthodontic treatment and follow-up of a patient with cerebral palsy and spastic quadriplegia. (27692425)
2016
36
Effects of Abnormal Oral Reflexes on Speech Articulation in Persian Speaking Children with Spastic Cerebral Palsy. (27375753)
2016
37
Sudden falls as a persistent complication of selective dorsal rhizotomy surgery in children with bilateral spasticity: report of 3 cases. (27104630)
2016
38
Immune-mediated spastic paraparesis accompanied with high titres of voltage-gated potassium channel complex antibodies and myokymia/fasciculation. (27084231)
2016
39
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. (27164716)
2016
40
CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia. (27292318)
2016
41
Novel Genetic, Clinical, and Pathomechanistic Insights into TFG-Associated Hereditary Spastic Paraplegia. (27492651)
2016
42
Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy. (27504360)
2016
43
Intramuscular nerve distribution of the hamstring muscles: Application to Treating Spasticity. (27213466)
2016
44
A 23 years follow-up study identifies GLUT1 deficiency syndrome initially diagnosed as complicated hereditary spastic paraplegia. (27725288)
2016
45
Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions. (27016404)
2016
46
Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution. (26847306)
2016
47
Two Cases of Human T-Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis Caused by Living-Donor Renal Transplantation. (27777805)
2016
48
Gradually Progressive Spastic Ataxia in a Young Man: Steadily Unsteady. (27942721)
2016
49
Cognitive Impairment Involving Social Cognition in SPG4 Hereditary Spastic Paraplegia. (27688599)
2016
50
Conserved pharmacological rescue of hereditary spastic paraplegia-related phenotypes across model organisms. (26744324)
2016

Variations for Spasticity

About this section

Expression for genes affiliated with Spasticity

About this section
Search GEO for disease gene expression data for Spasticity.

Pathways for genes affiliated with Spasticity

About this section

GO Terms for genes affiliated with Spasticity

About this section

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axon cytoplasmGO:19041159.3KIF1A, SPAST, SPG7

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1anterograde axonal transportGO:00080899.3KIF1A, SPAST, SPG7

Sources for Spasticity

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet